### 2.2.1 In vitro and physico-chemical data

A literature search was performed to collect available information on physico-chemical properties of moclobemide ([Table 1](#Table 1)).

| **Parameter**                   | **Unit**          | **Value**    | Source                                  | **Description**                                              |
| :------------------------------ | ----------------- | ------------ | --------------------------------------- | ------------------------------------------------------------ |
| MW<sup>+</sup>                  | g/mol             | 268.74       | [DrugBank DB01171](#5-references)       | Molecular weight                                             |
| pK<sub>a,base</sub><sup>+</sup> |                   | 6.2          | [IPCS ICHEM](#5-references)             | Acidic dissociation constant                                 |
| Solubility (pH)<sup>+</sup>     | mg/mL             | 3<br />(6.8) | [Moclobemide, INCHEM](#5-references)    | Aqueous Solubility                                           |
| logD                            |                   | 1.79         | [Pons 1990](#5-references)              | Distribution coefficient                                     |
| fu<sup>+</sup>                  | %                 | 50           | [MHRA Label Moclobemide](#5-references) | Fraction unbound in plasma                                   |
| Km_FMO (microsomes)             | mmol/L            | 0.77         | [Hoskins 2001](#5-references)           |                                                              |
| Vmax_FMO (microsomes)           | nmol/min/mg prot. | 1.39         | [Hoskins 2001](#5-references)           |                                                              |
| Renal Elimination               | ml/min/kg         | 0.03         | [Schoerlin 1987](#5-references)         | Schoerlin reports 2.6 ml/min/76kg                            |
| Ki_CYP2C19 (free)               | Âµmol/L            | 203.8        | [Kramer-Nielsen 1996](#5-references)    | The total ki value reported by Kramer was 210 umol/L and corrected with an fu_mic of 0.97 |

**Table 1:**<a name="Table 1"></a> Physico-chemical and *in-vitro* metabolization properties of moclobemide extracted from literature. *<sup>+</sup>: Value used in final model*

### 2.2.2 Clinical data

A literature search was performed to collect available clinical data on moclobemide in adults ([Table 2](#Table 2)).

| **Source**           | **Route** | **Dose [mg]/**  **Schedule \*** | **Pop.**     | Age [yrs] (mean or range) | Weight [kg] (mean or range) | **Sex** | **N** | **Form.** | **Comment**                       |
| -------------------- | --------- | ------------------------------- | ------------ | ------- | ----- | --------- | --------------------------------- | --------------------------------- | --------------------------------- |
| [Gram 1995](#5-references)<sup>+</sup> | p.o.                  | 300 s.d. / b.i.d.               | HV                | 26                        | -                           | m/f     | 8     | tablet           | EM + PM             |
| [Yu 2001](#5-references)<sup>+</sup> | p.o.                  | 300 s.d.                        | HV-Asian          | -                         | 60.3                        | m       | 8     | tablet           | EM, PM and EM+OMP40 |
| [Wiesel 1985](#5-references)<sup>+</sup> | p.o.                  | 50, 100, 200 s.d.               | HV or patient etc | 26.3                      | 75.8                        | m       | 6     | tablet           |                        |
| [Ignjatovic 2009](#5-references) | p.o.                  | 150 t.i.d.                      | Pat               | -                         | -                           | m/f     | 6     | tablet           |                        |
| [Dingemanse 1998](#5-references) | p.o.                  | 300 s.d.                        | HV                | -                         | -                           | f/m     | 12    | tablet           |                        |
| [Schoerlin 1987](#5-references)<sup>+</sup> | p.o. &  i.v. infusion | 150 t.i.d. /s.d.                | HV                | 27                        | 76                          | m       | 12    | tablet/ solution |                        |
| [Guentert 1990](#5-references)<sup>+</sup> | p.o.                  | 150 t.i.d.                      | HV                | 19-29                     | 59-86                       | m/f     | 14    | tablet           |                        |
| [Raaflaub 1984](#5-references)<sup>+</sup> | p.o. & i.v. infusion  | 50 s.d.                         | HV                | 42                        | 4                           | m       | 6     | tablet/ solution |                        |

**Table 2:**<a name="Table 2"></a> Literature sources of clinical concentration data of moclobemide used for model development and validation. *-: respective information was not provided in the literature source; \*:single dose unless otherwise specified; EM: extensive metabolizers; PM: poor metabolizers; <sup>+</sup>: Data used for final parameter identification*